- Home
- SWVL vs MDCX Comparison
SWVL vs MDCX Comparison
Compare SWVL & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.50
Company Overview
Basic Information| Metric | SWVL | MDCX |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United Arab Emirates | United States |
| Employees | 284 | 16 |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 16.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SWVL | MDCX |
|---|---|---|
| Price | $1.50 | $0.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 15.8K | ★ 1.9M |
| Earning Date | 04-20-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.31 | $0.25 |
| 52 Week High | $4.89 | $3.69 |
Technical Indicators
Market Signals| Indicator | SWVL | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 45.41 | 49.97 |
| Support Level | $1.34 | $0.27 |
| Resistance Level | $2.00 | $0.36 |
| Average True Range (ATR) | 0.16 | 0.03 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 29.54 | 54.39 |
Price Performance
Historical Comparison SWVL
MDCX
About SWVL Swvl Holdings Corp
Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.